Singapore markets close in 2 hours 8 minutes
Straits Times Index
3,388.24 +7.40 (+0.22%) Nikkei
27,606.46 -79.01 (-0.29%) Hang Seng
21,262.69 -36.01 (-0.17%) FTSE 100
7,864.71 +28.00 (+0.36%) BTC-USD
23,214.79 +264.19 (+1.15%) CMC Crypto 200
535.99 +10.03 (+1.91%)
Aditxt, Inc. (ADTX)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 1.4700 |
| Open | 1.4300 |
| Bid | 0.0000 x 1200 |
| Ask | 0.0000 x 3100 |
| Day's range | 1.3400 - 1.4700 |
| 52-week range | 1.0000 - 28.4900 |
| Volume | |
| Avg. volume | 198,503 |
| Market cap | 5.971M |
| Beta (5Y monthly) | 1.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7200 |
| Earnings date | 13 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
- Zacks
Is the Options Market Predicting a Spike in Aditx (ADTX) Stock?
Investors need to pay close attention to Aditx (ADTX) stock based on the movements in the options market lately.
- Business Wire
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO
RICHMOND, Va., January 03, 2023--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces the formation of a U.S.-based subsidiary Adimune, Inc. ("Adimune™) and its plans towards submission of a Clinical Trial Application ("CTA") for its immunotherapeutic technology drug candidate, ADI™-100 ("ADI™-100" or "ADI™"). The CTA application will request a
- Zacks
Implied Volatility Surging for Aditx Therapeutics (ADTX) Stock Options
Investors need to pay close attention to Aditx Therapeutics (ADTX) stock based on the movements in the options market lately.
© 2023 Yahoo. All rights reserved.
